ENXTBR:ARGXBiotechs
Why argenx (ENXTBR:ARGX) Is Up 7.0% After New Long‑Term VYVGART Autoimmune Data Release - And What's Next
Earlier this week, argenx SE reported new 52‑ and 72‑week data on VYVGART (efgartigimod) in myositis and Sjogren’s disease at the EULAR 2026 Congress, showing sustained clinical improvements and a consistent safety profile in both open‑label extension studies.
The results reinforce the potential relevance of FcRn blockade across multiple autoimmune rheumatic conditions, suggesting VYVGART could address a broader pool of difficult‑to‑treat patients beyond its current indications.
Next, we’ll...